High-throughput screening of SARS-CoV-2 main and papain-like protease inhibitors

Abstract

The global COVID-19 coronavirus pandemic has infected over 109 million people, leading to over 2 million deaths up to date and still lacking of effective drugs for patient treatment. Here, we screened about 1.8 million small molecules against the main protease (M^pro) and papain like protease (PL^pro), two major proteases in severe acute respiratory syndrome-coronavirus 2 genome, and identified 1851M^pro inhibitors and 205 PL^pro inhibitors with low nmol/L activity of the best hits. Among these inhibitors, eight small molecules showed dual inhibition effects on both M^pro and PL^pro, exhibiting potential as better candidates for COVID-19 treatment. The best inhibitors of each protease were tested in antiviral assay, with over 40% of M^pro inhibitors and over 20% of PL^pro inhibitors showing high potency in viral inhibition with low cytotoxicity. The X-ray crystal structure of SARS-CoV-2 M^pro in complex with its potent inhibitor 4a was determined at 1.8 Å resolution. Together with docking assays, our results provide a comprehensive resource for future research on anti-SARS-CoV-2 drug development.

Keywords

high-throughput screening / SARS / CoV-2 / main / papain-like / proteases

References

[1] Adhikari SP , Meng S , Wu YJ et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty 2020; 9: 29.

[2] Baez-Santos YM , St John SE , Mesecar AD . The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds. Antiviral Res 2015; 115: 21- 38.

[3] Bai Y , Ye F , Feng Y et al. Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir. Signal Transduct Target Ther 2021; 6: 51.

[4] Calistri A , Munegato D , Carli I et al. The ubiquitin-conjugating system: multiple roles in viral replication and infection. Cells 2014; 3: 386- 417.

[5] Cao B , Wang Y , Wen D et al. A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020; 382: 1787- 1799.

[6] Clementz MA , Chen Z , Banach BS et al. Deubiquitinating and interferon antagonism activities of coronavirus papain-like proteases. J Virol 2010; 84: 4619- 4629.

[7] Daczkowski CM , Goodwin OY , Dzimianski JV et al. Structurally guided removal of DeISGylase biochemical activity from papain-like protease originating from middle east respiratory syndrome coronavirus. J Virol 2017; 91: e01067- 17.

[8] Dai W , Zhang B , Jiang XM et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science 2020a; 368: 1331- 1335.

[9] Dai W , Zhang B , Su H et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science 2020b; 368: 1331- 1335.

[10] Daviet L , Colland F . Targeting ubiquitin specific proteases for drug discovery. Biochimie 2008; 90: 270- 283.

[11] Devaraj SG , Wang N , Chen Z et al. Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus. J Biol Chem 2007; 282: 32208- 32221.

[12] Douangamath A , Fearon D , Gehrtz P et al. Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease. Nat Commun 2020; 11: 5047.

[13] Durante-Mangoni E , Andini R , Bertolino L et al. Early experience with remdesivir in SARS-CoV-2 pneumonia. Infection 2020; 48: 779- 782.

[14] Freitas BT , Durie IA , Murray J et al. Characterization and noncovalent inhibition of the deubiquitinase and deISGylase activity of SARS-CoV-2 papain-like protease. ACS Infect Dis. 2020; 6: 2099- 2109.

[15] Frieman M , Ratia K , Johnston RE et al. Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling. J Virol 2009; 83: 6689- 6705.

[16] Friesner RA , Banks JL , Murphy RB et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004; 47: 1739- 1749.

[17] Fu L , Ye F , Feng Y et al. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nat Commun 2020; 11: 4417.

[18] Grein J , Ohmagari N , Shin D et al. Compassionate use of Remdesivir for patients with severe Covid-19. N Engl J Med 2020a; 382: 2327- 2336.

[19] Grein J , Ohmagari N , Shin D et al. Compassionate use of Remdesivir for patients with severe Covid-19. N Engl J Med 2020b; 382: 2327- 2336.

[20] Guy RK , DiPaola RS , Romanelli F et al. Rapid repurposing of drugs for COVID-19. Science 2020; 368: 829- 830.

[21] Hoffman RL , Kania RS , Brothers MA et al. Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19. J Med Chem 2020; 63: 12725- 12747.

[22] Jin Z , Du X , Xu Y et al. Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. Nature 2020a; 582: 289- 293.

[23] Jin Z , Du X , Xu Y et al. Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. Nature 2020b; 582: 289- 293.

[24] Kneller DW , Galanie S , Phillips G et al. Malleability of the SARS-CoV-2 3CL M(pro) active-site cavity facilitates binding of clinical antivirals. Structure 2020; 28: 1313- 1320.

[25] Lin MH , Moses DC , Hsieh CH et al. Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes. Antiviral Res 2018; 150: 155- 163.

[26] Lobo-Galo N , Terrazas-Lopez M , Martinez-Martinez A et al. FDAapproved thiol-reacting drugs that potentially bind into the SARS-CoV-2 main protease, essential for viral replication. J Biomol Struct Dyn 2021; 39: 3419- 3427.

[27] Lockbaum GJ , Reyes AC , Lee JM et al. Crystal structure of SARS-CoV-2 main protease in complex with the non-covalent inhibitor ML188. Viruses 2021; 13: 174.

[28] Ma-Lauer Y , Carbajo-Lozoya J , Hein MY et al. p53 down-regulates SARS coronavirus replication and is targeted by the SARS-unique domain and PLpro via E3 ubiquitin ligase RCHY1. Proc Natl Acad Sci USA 2016; 113: E5192- 201.

[29] Mielech AM , Kilianski A , Baez-Santos YM et al. MERS-CoV papain-like protease has deISGylating and deubiquitinating activities. Virology 2014; 45: 64- 70.

[30] Pillaiyar T , Manickam M , Namasivayam V et al. An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy. J Med Chem 2016; 59: 6595- 6628.

[31] Qiao J , Li YS , Zeng R et al. SARS-CoV-2 M(pro) inhibitors with antiviral activity in a transgenic mouse model. Science 2021; 371: 1374- 1378.

[32] Ratia K , Pegan S , Takayama J et al. A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc Natl Acad Sci USA 2008; 105: 16119- 16124.

[33] Ratia K , Saikatendu KS , Santarsiero BD et al. Severe acute respiratory syndrome coronavirus papain-like protease:structure of a viral deubiquitinating enzyme. Proc Natl Acad Sci USA 2006; 103: 5717- 5722.

[34] Sacco MD , Ma C , Lagarias P et al. Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M(pro) and cathepsin L. Sci Adv 2020; 6: eabe0751.

[35] Sali A . Comparative protein modeling by satisfaction of spatial restraints. Mol Med Today 1995; 1: 270- 277.

[36] Su HX , Yao S , Zhao WF et al. Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients. Acta Pharmacol Sin 2020; 41: 1167- 1177.

[37] Sulea T , Lindner HA , Purisima EO et al. Binding site-based classification of coronaviral papain-like proteases. Proteins 2006; 62: 760- 775.

[38] Tan J , Verschueren KH , Anand K et al. pH-dependent conformational flexibility of the SARS-CoV main proteinase (M(pro)) dimer:molecular dynamics simulations and multiple X-ray structure analyses. J Mol Biol 2005; 354: 25- 40.

[39] Tchesnokov EP , Feng JY , Porter DP et al. Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by Remdesivir. Viruses 2019; 11: 326- 341.

[40] Walker PGT , Whittaker C , Watson OJ et al. The impact of COVID-19 and strategies for mitigation and suppression in low- and middle-income countries. Science 2020; 369: 413- 422.

[41] Wu C , Liu Y , Yang Y et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B 2020a; 10: 766- 788.

[42] Wu F , Zhao S , Yu B et al. A new coronavirus associated with human respiratory disease in China. Nature 2020b; 579: 265- 269.

[43] Yang KS , Ma XR , Ma Y et al. A quick route to multiple highly potent SARS-CoV-2 main protease inhibitors^*. ChemMedChem 2020.

[44] Yang H , Xie W , Xue X et al. Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol 2005; 3: e324.

[45] Yin W , Mao C , Luan X et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by Remdesivir. Science 2020; 368: 1499- 1504.

[46] Zhang L , Lin D , Sun X et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors. Science 2020; 368: 409- 412.

[47] Zumla A , Chan JF , Azhar EI et al. Coronaviruses—drug discovery and therapeutic options. Nat Rev Drug Discov 2016; 15: 327- 347.

RIGHTS & PERMISSIONS

2022 The Author(s) 2022. Published by Oxford University Press on behalf of Higher Education Press.